Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib withdrawal trial in pediatric juvenile idiopathic arthritis
MOH_2018-03-26_002283Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in juvenile idiopathic arthritis (JIA) (3 arms), sponsored by Pfizer. Primary endpoint: Disease flare rate at Week 26 of the double-blind phase. Started Oct 2015; status: completed.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on MOH_2018-03-26_002283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-26_002283.